The developer of the device was guided virtually by experts from KSOU, who selected and validated the appropriate biomarkers for cardiovascular health monitoring.
| Photo Credit: M.A. SRIRAM
The faculty of Department of Studies in Microbiology in the Karnataka State Open University (KSOU) in Mysuru has played a key role in the development of an Artificial Intelligence (AI)-driven device for detection of early signs of cardiovascular stress.
The MyoBioScan device, developed by Ravichandra Mulpuri, an Indian-origin researcher based in the US, is a non-invasive and diagnostic tool aimed at enabling real-time monitoring of cardiovascular health. By capturing and analysing subtle physiological changes, the device, described as a “wearable patch”, seeks to alert users to potential heart-related issues before they become life threatening.
The MyoBioScan, whichhas been featured in the April-June 2025 issue of the International Journal on Science and Technology (IJSAT), is in its prototype and validation stage. “The device integrates multi-channel ECG acquisition with sweat-based biochemical sensing for key cardiac biomarkers”.
The developer, Mr. Mulpuri, was guided virtually by experts from the KSOU, viz. Niranjan Raj and Syed Baker, who selected and validated the appropriate biomarkers for cardiovascular health monitoring.
The device, ideally worn during exercises like running or training in the gym, will analyse the person’s sweat for various hormones and protein complexes that serve as cardiovascular biomarkers, said Mr. Baker.
“The sweat-based biomarkers like troponin-I, NT-proBNP, lactate, cortisol, and pH, provide an insight into cardiovascular health,” he said. The KSOU faculty’s academic mentorship was instrumental in shaping the scientific backbone of MyoBioScan, enhancing both its clinical relevance and technical design.
The device has been designed to give three signals based on its analysis. “Normal — keep monitoring, consult a medical professional, and emergency,” he said.
Quoting Mr. Mulpuri, Mr. Baker said that the device had the potential to become a low-cost, accessible diagnostic tool that can transform how early cardiovascular risks can be detected and managed.
The abstract of MyoBioScan in IJSAT said a pilot study evaluated the device for its performance in 80 participants, including healthy individuals and those with diagnosed conditions such as atrial fibrillation, myocardial ischemia, and early-stage heart failure.
“Subclinical abnormalities were detected in 4 asymptomatic individuals and confirmed through clinical follow-up. Sweat biomarker levels significantly differed between healthy and stressed participants, showing strong correlation with laboratory standards. User feedback revealed high satisfaction in terms of comfort, clarity of app feedback and trust in results, with over 90% expressing interest in long-term use,” the abstract said.
Published – July 11, 2025 06:38 pm IST
